Bright Minds Biosciences (DRUG) Competitors $39.75 +0.93 (+2.40%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends DRUG vs. DNTH, RAPP, AUTL, OCS, CGEM, PRTA, TRDA, ABUS, TECX, and STOKShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), Autolus Therapeutics (AUTL), Oculis (OCS), Cullinan Therapeutics (CGEM), Prothena (PRTA), Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), Tectonic Therapeutic (TECX), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Dianthus Therapeutics Rapport Therapeutics Autolus Therapeutics Oculis Cullinan Therapeutics Prothena Entrada Therapeutics Arbutus Biopharma Tectonic Therapeutic Stoke Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends. Does the MarketBeat Community believe in DRUG or DNTH? Dianthus Therapeutics received 20 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 100.00% of users gave Bright Minds Biosciences an outperform vote while only 95.65% of users gave Dianthus Therapeutics an outperform vote. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes2100.00% Underperform VotesNo VotesDianthus TherapeuticsOutperform Votes2295.65% Underperform Votes14.35% Which has more volatility and risk, DRUG or DNTH? Bright Minds Biosciences has a beta of -7.06, suggesting that its share price is 806% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Does the media refer more to DRUG or DNTH? In the previous week, Dianthus Therapeutics had 5 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 0 mentions for Bright Minds Biosciences. Dianthus Therapeutics' average media sentiment score of 1.00 beat Bright Minds Biosciences' score of 0.95 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bright Minds Biosciences Positive Dianthus Therapeutics Positive Which has stronger valuation & earnings, DRUG or DNTH? Bright Minds Biosciences has higher earnings, but lower revenue than Dianthus Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$5.47M-$0.68-58.46Dianthus Therapeutics$5.37M133.86-$43.56M-$2.50-9.71 Do analysts prefer DRUG or DNTH? Bright Minds Biosciences currently has a consensus target price of $75.00, indicating a potential upside of 88.68%. Dianthus Therapeutics has a consensus target price of $46.43, indicating a potential upside of 91.30%. Given Dianthus Therapeutics' higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Is DRUG or DNTH more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Bright Minds Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -58.55% -53.79% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Do insiders and institutionals hold more shares of DRUG or DNTH? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryDianthus Therapeutics beats Bright Minds Biosciences on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$176.25M$6.86B$5.17B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-58.4610.75127.7717.55Price / SalesN/A285.811,261.39139.05Price / CashN/A56.6541.0437.95Price / Book36.145.394.894.92Net Income-$5.47M$151.81M$119.40M$225.78M7 Day Performance6.40%-5.54%14.54%-1.47%1 Month Performance0.35%0.33%17.43%5.36%1 Year Performance2,550.00%16.04%35.31%22.71% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.6973 of 5 stars$39.75+2.4%$75.00+88.7%+2,550.0%$176.25MN/A-58.46N/ADNTHDianthus Therapeutics1.6496 of 5 stars$24.36+2.3%$46.43+90.6%+235.7%$721.06M$2.83M-9.5280Positive NewsRAPPRapport Therapeutics1.8464 of 5 stars$19.57+4.3%$35.00+78.8%N/A$715.87MN/A0.00N/APositive NewsAUTLAutolus Therapeutics2.7841 of 5 stars$2.63+5.6%$10.40+295.4%-50.3%$699.82M$1.70M-2.06330OCSOculis2.1933 of 5 stars$17.06-0.2%$29.20+71.2%+74.5%$691.00M$980,000.00-8.852CGEMCullinan Therapeutics1.611 of 5 stars$11.81+0.5%$31.67+168.1%+39.4%$687.67M$18.94M-4.1430Short Interest ↑News CoveragePRTAProthena1.807 of 5 stars$12.74-0.4%$61.83+385.3%-64.9%$685.53M$133.35M-5.16173News CoverageTRDAEntrada Therapeutics3.1433 of 5 stars$18.25+3.3%$25.67+40.6%+32.4%$682.92M$129.01M11.11110Positive NewsABUSArbutus Biopharma2.4851 of 5 stars$3.57+2.6%$5.50+54.1%+54.5%$676.48M$18.14M-8.0973Positive NewsTECXTectonic Therapeutic3.1742 of 5 stars$45.58+0.6%$72.25+58.5%N/A$672.44MN/A-7.70120Positive NewsSTOKStoke Therapeutics4.0995 of 5 stars$12.28+1.8%$20.83+69.7%+136.3%$650.47M$8.78M-5.74100 Related Companies and Tools Related Companies Dianthus Therapeutics Competitors Rapport Therapeutics Competitors Autolus Therapeutics Competitors Oculis Competitors Cullinan Therapeutics Competitors Prothena Competitors Entrada Therapeutics Competitors Arbutus Biopharma Competitors Tectonic Therapeutic Competitors Stoke Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRUG) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
